2 unchanged sentences
Most of the issues raised by such claims are highly complex and subject to substantial uncertainties.
−Removed: For a description of risks relating to these legal proceedings, see “Part II—Item 1A—Risk Factors” of this Quarterly Report, including the discussion under the headings entitled “Risks Related to Our Intellectual Property.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain;
+Added: For a description of risks relating to these legal proceedings, see “Part II—Item 1A—Risk Factors” of this Quarterly Report, including the discussion under the heading entitled “Risks Related to Our Intellectual Property.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain;
therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment.
2 unchanged sentences
On June 13, 2023, Pharmacyclics LLC (“Pharmacyclics”) filed a complaint in the U.S.
−Removed: District Court for the District of Delaware (the “Court”) against the Company and its subsidiary, BeiGene USA, Inc., alleging that BRUKINSA infringes Pharmacyclics’ U.S Patent No.
+Added: District Court for the District of Delaware (the “Court”) against the Company and its subsidiary, BeiGene USA, Inc., which subsequently changed its name to BeOne Medicines USA, Inc., alleging that BRUKINSA infringes Pharmacyclics’ U.S Patent No.
11,672,803 issued on June 13, 2023 (the “‘803 patent”).
2 unchanged sentences
On October 12, 2023, the Court entered a joint stipulation filed by the parties to stay the infringement suit pending resolution of a petition for post-grant review (“PGR”) of the ‘803 Patent with the U.S.
−Removed: Patent and Trademark Office (“USPTO”) that was later filed by BeiGene on November 1, 2023.
−Removed: On April 29, 2025, the USPTO issued a Final Written Decision that invalidated all claims of the ‘803 patent challenged by BeiGene.
+Added: Patent and Trademark Office (the “USPTO”) that was later filed by the Company on November 1, 2023.
+Added: On May 1, 2024, the USPTO granted the Company’s PGR petition.
+Added: On April 29, 2025, the USPTO issued a Final Written Decision (“FWD”) that invalidated all challenged claims of the ‘803 patent.
+Added: On May 29, 2025, Pharmacyclics filed a request for Director Review of the USPTO’s FWD.
+Added: On July 17, 2025, the USPTO denied Pharmacyclics’ request.
AbbVie Litigation
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.